EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA

Yusuke Kasuga iD, Ryota Ouda, Masashi Watanabe iD, Xin Sun, Miki Kimura, Shigetsugu Hatakeyama iD, Koichi S Kobayashi iD

Proceedings of the National Academy of Sciences · 13.06.2023 · 120 (24)

DOI: 10.1073/pnas.2218955120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 06.06.2023. Verfasst von Yusuke Kasuga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Hokkaido University, Graduate School of Medicine, Sapporo 060-8638, Japan. Hauptthemen laut MEDLINE: F-Box Proteins, Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEXT | Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Takeda Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major histocompatibility complex (MHC) class I and II molecules play critical roles in the activation and regulation of adaptive immunity through antigen presentation to CD8+ and CD4+ T cells, respectively. Strict regulation of MHC expression is critical for proper immune responses. CIITA (MHC class II transactivator), an NLR (nucleotide-binding domain, leucine-rich-repeat containing) protein, is a master regulator of MHC class II (MHC-II) gene transcription. Although it has been known that CIITA activity is regulated at the transcriptional and protein levels, the mechanism to determine CIITA protein level has not been elucidated. Here, we show that FBXO11 is a bona fide E3 ligase of CIITA and regulates CIITA protein level through ubiquitination-mediated degradation. A nonbiased proteomic approach for CIITA-binding protein identified FBXO11, a member of the Skp1–Cullin-1–F-box E3 ligase complex, as a binding partner of CIITA but not MHC class I transactivator, NLRC5. The cycloheximide chase assay showed that the half-life of CIITA is mainly regulated by FBXO11 via the ubiquitin–proteasome system. The expression of FBXO11 led to the reduced MHC-II at the promoter activity level, transcriptional level, and surface expression level through downregulation of CIITA. Moreover, human and mouse FBXO11 –deficient cells display increased levels of MHC-II and related genes. In normal and cancer tissues, FBXO11 expression level is negatively correlated with MHC-II. Interestingly, the expression of FBXO11 , along with CIITA , is associated with prognosis of cancer patients. Therefore, FBXO11 is a critical regulator to determine the level of MHC-II, and its expression may serve as a biomarker for cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

F-Box ProteinsNeoplasmsAnimalsHumansMiceGenes, MHC Class IIHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensIntracellular Signaling Peptides and ProteinsProtein-Arginine N-MethyltransferasesProteomicsTrans-ActivatorsUbiquitinUbiquitin-Protein LigasesNuclear Proteins

Stichwörter der Autor:innen

CIITAFBXO11MHC-IINLRC5ubiquitination

Substanzen

F-Box ProteinsHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensIntracellular Signaling Peptides and ProteinsProtein-Arginine N-MethyltransferasesTrans-ActivatorsUbiquitinUbiquitin-Protein LigasesFBXO11 protein, human

Autor:innen und Institutionen

  • Department of Immunology, Hokkaido University, Graduate School of Medicine, Sapporo 060-8638, Japan.
  • Department of Biochemistry, Hokkaido University, Graduate School of Medicine, Sapporo 060-8638, Japan.
  • Hokkaido University, Institute of Vaccine Research and Development, Sapporo 060-8638, Japan.
  • Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, Bryan, TX 77807.

ORCID-Profile: Yusuke Kasuga, Masashi Watanabe, Shigetsugu Hatakeyama, Koichi S Kobayashi

Förderung

  • MEXT | Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Takeda Science Foundation
  • Bristol Myers Squibb
  • SENSHIN Medical Research Foundation
  • Hitachi Global Foundation
  • Kobayashi Foundation
  • Toyo Suisan Foundation

Zitieren

APA

Kasuga, Y., Ouda, R., Watanabe, M., Sun, X., Kimura, M., Hatakeyama, S., & Kobayashi, K. S. (2023). FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA. Proceedings of the National Academy of Sciences, 120(24). https://doi.org/10.1073/pnas.2218955120

Vancouver

Kasuga Y, Ouda R, Watanabe M, Sun X, Kimura M, Hatakeyama S, et al. FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA. Proceedings of the National Academy of Sciences. 2023;120(24). doi:10.1073/pnas.2218955120

BibTeX
@article{Kasuga2023,
  author = {Kasuga, Yusuke and Ouda, Ryota and Watanabe, Masashi and Sun, Xin and Kimura, Miki and Hatakeyama, Shigetsugu and Kobayashi, Koichi S},
  title = {FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  volume = {120},
  number = {24},
  doi = {10.1073/pnas.2218955120}
}
Kostenlos starten →